JCCC Research Seminar featuring Dr. H. David Ulmert
Harnessing androgen-receptor pathway activation for targeted alpha particle radioimmunotherapy of breast cancer
- Date: October 18, 2018 12:00 PM - 1:00 PM
- Location: 53-105 CHS
10833 Le Conte Ave.
Los Angeles, California 90095
H. David Ulmerts, M.D., Ph.D.
Director, Preclinical Theranostics Program
Department of Molecular and Medical Pharmacology
David Geffen School of Medicine at UCLA
Dr. H. David Ulmert's clinical research is focused on the study of risk factors and biomarkers related to clinically diagnosed prostate cancer and definitive end-points in non-screened cohorts. The findings of these studies extend into his translational research, which center on development of novel in vivo strategies targeting enzymes regulated by the molecular pathways that drive the disease. The overarching goal is to apply these specific tissue targeting vehicles for multimodal molecular imaging strategies, as well as for carriers of therapeutic agents.
Light lunch served
Sponsored by the JCCC Cancer Molecular Imaging and Theranostics program.